Cervical Cancer Screening
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and reimbursement criteria for cervical cancer screening (Pap cytology, high-risk HPV testing, and co-testing) for individuals with a cervix under Blue Cross Blue Shield of North Carolina.
Separated statement in When Not Covered to make two statements that now read: 'Reimbursement is not allowed for testing for low-risk HPV.' and 'Reimbursement is not allowed for all other indications not discussed above for cervical screening.'
Coverage criteria #1 edited to include immunocompromised, therefore removed immunocompromised from coverage criteria #4 and #6.
Coverage criteria 1a changed from individuals under 30 to individuals of all ages; added 'high-risk' to coverage criteria 1b; edited coverage criteria #5 to add 'nucleic acid' for clarity.
Added CPT code 87626 to Billing/Coding section, effective 1/1/2025.
Added 0502U to Billing/Coding section, effective 10/1/24.
Coverage Criteria for Cervical Cancer Screening
Covered screening by age and risk
Covered when ALL of the following age- and risk-specific criteria are met:
Immunocompromised or immunosuppressed status permits more frequent screening per policy.
Applies to average-risk, asymptomatic, immunocompetent individuals.
Multiple acceptable screening modalities per policy.
High-risk exception to general cessation of routine screening.
Genotyping for HPV-16/18 allowed following a pooled positive hr-HPV result.
Applies to those with prior abnormal results or other defined high-risk status.
Screening and management criteria
Coverage-aligned screening recommendations from cited guideline bodies (USPSTF, ACS, ASCCP, NCCN, NCI, ACOG) summarized as criteria sets
Per USPSTF and reflected in policy.
Per USPSTF (2018) and ACS (2020) guidance.
Per USPSTF and NCI recommendations.
ASCCP 2019 guidance for non-HIV immunocompromised women (see policy tables).
Per ACOG and CDC recommendations and ASCCP management guidance.
Enduring Consensus 2025 update recommendations and ASCCP statements.
Guideline-based coverage and triage criteria
Guideline-based recommendations and triage algorithms summarized from multiple specialty societies and public health agencies.
Interim 2015 guidance and subsequent society statements support these intervals.
ACOG, CDC, ASCO and ASCCP guidance emphasize genotyping and reflex testing to determine colposcopy referral.
ACOG recommends prolonged surveillance after treatment due to persistent elevated risk.
US HHS HIV OI guidelines summarized in policy.
ASCO 2022 resource-stratified guidance.
When Covered / General criteria
Policy provides coverage when medical necessity criteria and guidelines are met; coverage criteria were updated and clarified over time.
Policy implementation and subsequent updates document this coverage stance and clarifications.
Reimbursement is not allowed for cervical cancer screening (cervical cytology or hr‑HPV testing) for individuals younger than 21 years except where specific covered exceptions are separately addressed. The policy also states that routine screening is not allowed for individuals >65 years of age who are not immunocompromised, immunosuppressed, or otherwise considered high‑risk for cervical cancer. Claims performed outside these age‑based boundaries may be denied.
Screening is not recommended and reimbursement is not allowed for individuals who have undergone hysterectomy with removal of the cervix for benign disease and who have no history of cervical cancer or precancer; guideline sources conclude screening in persons without a cervix is not helpful and should not be performed.
Primary high‑risk HPV (hrHPV) screening should not be initiated before age 25. When used as primary screening, a negative hrHPV test should prompt rescreening no sooner than every 3 years; some guideline bodies recommend hrHPV DNA screening at up to 5‑year intervals for specified age groups. For persons at higher risk (for example, immunocompromised individuals or others identified in guideline tables), screening may be started earlier and performed more frequently (for many of these individuals, annual cytology or tailored co‑testing is recommended).
Reimbursement is not allowed for testing that targets low‑risk HPV types (the genotypes associated with genital warts); professional guidance (Choosing Wisely/AAFP) states low‑risk HPV testing has no medical indication and should not be performed.
Reimbursement is not allowed for other indications for cervical screening that are not explicitly described as covered in this policy. The policy lists multiple not‑covered situations (see the When Covered section for the allowed, age‑ and risk‑specific criteria); testing performed for indications outside those criteria may be denied.
Routine cervical cancer screening is generally discontinued after age 65 for persons who are not immunocompromised, immunosuppressed, or otherwise high‑risk, provided they have had adequate prior screening. The USPSTF and policy language indicate screening beyond this age in average‑risk individuals is considered not beneficial and is typically not covered.
Consistent with USPSTF guidance, routine screening is not recommended for individuals younger than 21 or for those older than 65 with adequate prior screening. These age‑based limits reflect guideline assessments that screening in these groups provides no net benefit and may increase harms from false positives and unnecessary procedures.
Choosing Wisely/American Academy of Family Physicians recommends against low‑risk HPV testing (HPV types that cause genital warts). The policy adopts this stance and specifies that low‑risk HPV testing is not medically indicated and is not reimbursed.
Historical policy changes: prior age‑based restrictions that limited reimbursement for individuals under 21 only to specific high‑risk situations were removed effective 12/5/2023. The policy language was updated to clarify coverage criteria and to separate noncoverage statements for low‑risk HPV testing and other non‑covered indications.
Billing and Applicable Service Codes
| 0502U | Applicable service code |
| 87623 | HPV test (code listed as applicable) |
| 87624 | HPV test (applicable) |
| 87625 | HPV test (applicable) |
| 87626 | HPV test (added to Billing/Coding effective 1/1/2025) |
| 88141 | Cervical cytology codes (applicable) |
| 88142 | Cervical cytology codes (applicable) |
| 88143 | Cervical cytology codes (applicable) |
| 88147 | Cervical cytology codes (applicable) |
| 88148 | Cervical cytology codes (applicable) |
Provider Actions, Documentation, and Billing Guidance
Prior authorization
No prior authorization statements are present in this portion of the policy.
Expedited treatment — document risk assessment & counseling
Expedited treatment (treatment without a preceding colposcopic biopsy demonstrating CIN2+) is preferred for selected nonpregnant patients ≥25 years (for example HSIL cytology with concurrent HPV‑16) when immediate CIN3+ risk meets thresholds; document shared decision‑making, risk assessment, and counseling in the medical record.
- Expedited treatment is preferred when immediate risk of CIN3+ ≥60% and acceptable for risks 25–60%.
- Document counseling and risk assessment; expedited treatment is only possible if cytology is performed (so reflex cytology must be available).
Applicable service codes listed — verify reimbursement
Applicable service codes are listed in the Billing/Coding section but inclusion does not guarantee reimbursement; verify reimbursement rules and any administrative/prior authorization requirements with BCBSNC.
- Listed applicable service codes include: 0502U, 87623–87626, multiple cytology CPT/HCPCS codes, and others (see billing/coding list).
- Check BCBSNC Administrative Policies and the member benefit for coverage and reimbursement details.
Applicable service codes — verify benefits & medical necessity
Inclusion of codes in the billing/coding list indicates applicable service codes but presence in the list does not guarantee payment; verify member benefits and medical necessity for each claim.
- The policy explicitly states that inclusion of a code does not guarantee reimbursement.
- Confirm coverage in the Member's Benefit Booklet and BCBSNC administrative policies before billing.
Provider action (reserved)
(No provider action content provided in source for this placeholder.)
HPV‑16/18 positive — refer for colposcopy with biopsy
When HPV‑16 or HPV‑18 is detected, additional diagnostic evaluation such as colposcopy with biopsy is recommended even if cytology is negative; if reflex testing from the same specimen is not feasible, proceed directly to colposcopy and collect triage specimens at that visit.
- HPV‑16 and HPV‑18 infections have the highest risk for CIN3 and occult cancer and typically prompt colposcopy even with NILM cytology.
- If HPV16/18 positive and same‑sample additional testing is not feasible, patients should proceed directly to colposcopy.
Applicable service codes — confirm coverage
Additional applicable service codes are listed in the billing/coding section; inclusion does not guarantee reimbursement—confirm with BCBSNC and member benefits.
Applicable service codes — verify before billing
Additional applicable service codes are listed in the billing/coding section; presence on the list does not ensure payment—verify benefits and medical necessity prior to billing.
Benefit verification and clinical documentation
Verify the member's benefit design in the Member's Benefit Booklet prior to applying policy criteria and document clinical indications, age, risk status, and prior screening history in the medical record to support coverage.
- Document clinical indication, patient age, risk factors (e.g., immunocompromised status, prior abnormal cytology, DES exposure), and prior screening history.
- Confirm benefit availability in the Member's Benefit Booklet as member benefits may vary by plan.
Reflex triage testing — use same specimen or collect at colposcopy
For primary HPV screening, perform reflex cytology or other triage testing from the same laboratory specimen for all positive HPV tests; if same‑specimen reflex testing is not feasible, proceed to colposcopy and collect the additional triage specimen at that visit.
- Reflex triage testing from the same specimen is recommended because results inform colposcopy practice and management.
- Reflex cytology is required to enable expedited treatment decisions when indicated.
Medical records may be requested — letters alone often insufficient
BCBSNC may request medical records to determine medical necessity; letters alone are insufficient unless they include all information needed for a medical necessity determination.
- Maintain complete medical records supporting the indication for screening and any abnormal results, diagnostic procedures, and counseling.
- Letters of support may be useful but must include all required clinical details to substitute for records.
Supporting documentation — include all required clinical details
When medical records are requested, letters of support or explanation may be useful but are not sufficient unless they include all specific information needed to make a medical necessity determination; ensure records include relevant clinical details.
- Include specific clinical information (age, risk factors, prior screening/results, reason for test) in records or letters if submitted.
- Failure to provide requested documentation can result in denial or nonpayment.
Triggers for denial — screening performed in excluded situations
Claims for cervical cancer screening can be denied when the service is performed for individuals under age 21 (except as specifically addressed), for routine screening in individuals over 65 who are not high‑risk, for individuals post‑hysterectomy with no history of cervical cancer/precancer, for testing for low‑risk HPV, or for other indications not listed as covered.
- Do not submit claims for routine screening for individuals <21 (unless an exception in policy applies).
- Do not submit routine screening claims for individuals >65 who are not high‑risk (had adequate prior screening).
- Do not bill for low‑risk HPV testing—reimbursement is not allowed.
Age‑based screening limits — follow guideline age ranges
Screening outside the recommended age ranges (younger than 21 or older than 65 with adequate prior screening) is discouraged and may result in noncoverage or denial depending on benefit rules; follow USPSTF/other guideline age limits when applying for coverage.
- USPSTF recommends against routine screening for individuals younger than 21 and older than 65 with adequate prior screening.
- Confirm exceptions (e.g., high‑risk individuals) and document rationale when screening outside typical age ranges.
Codes listed do not guarantee payment — retain supporting documentation
Inclusion of a code in the billing/coding section does not guarantee reimbursement; BCBSNC may request medical records to determine medical necessity, so retain documentation supporting the billed service.
- Keep complete medical records showing clinical indication, prior screening history, and risk status.
- Verify reimbursement and any prior authorization requirements before submitting claims.
Medical records may be requested — missing documentation risks denial
BCBSNC may request medical records for determination of medical necessity; absence of required documentation can trigger denial or nonpayment. Ensure medical records fully document the indication, findings, and management.
- Document age, risk factors, prior screening results, reason for testing, and any reflex or follow‑up testing performed.
- Provide requested records promptly to avoid denial or delays in payment.
Background and Rationale
Cervical cancer screening aims to detect precancerous lesions and invasive disease using cytology (Pap), high‑risk HPV testing, and colposcopy when indicated. High‑risk HPV types, particularly HPV‑16 and HPV‑18, are strongly associated with cervical intraepithelial neoplasia and cervical cancer. Screening intervals and modality selection vary by age and risk: for example, cytology every 3 years for ages 21–29, and for ages 30–65 either cytology every 3 years, hr‑HPV testing alone every 5 years, or co‑testing every 5 years. Colposcopy with biopsy is the diagnostic follow‑up when screening or triage testing indicates high risk, and reflex cytology or triage testing from the same specimen is recommended for positive primary hrHPV results to guide management.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.